Human serum albumin

ApprovedSmall molecule

FFresenius

Human serum albumin is one of 114 small molecule programs targeting Ascites. It is currently in Approved.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

MortalityActive, not recruiting

Head InjuryActive, not recruiting

CirrhosisActive, not recruiting

AscitesPhase 2/Phase 3

Active, not recruiting

MortalityPreclinical

Active, not recruiting

Head InjuryPhase 2/Phase 3

Active, not recruiting

CirrhosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Human serum albumin

FFresenius

Approved

1 2

Proamatine

Takeda

Preclinical

9 3

Crestor

AstraZeneca

Preclinical

2 4

Farxiga

AstraZeneca

Preclinical

1 5

Revia

Teva

Preclinical

1 6

Cipro

Bayer

Preclinical

1 7

Thalomid

Bristol-Myers Squibb

Preclinical

1 8

Dobutrex

Eli Lilly

Preclinical

1 9

Azulfidine

Pfizer

Preclinical

1 10

HEPCLUDEX

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Head Injury1 trial

High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury

Unknown status·UUniversity Hospital, Angers·Phase 2/3·NCT00152685·40 enrolled

Phase II1 trial

Phase II/III of Recombinant Human Serum Albumin

Completed·PProtgen Ltd·Phase 2/3·NCT05858853·92 enrolled

Cirrhosis1 trial

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Completed·PProtgen Ltd·Phase 1·NCT05249374·36 enrolled

Cardiac Surgery1 trial

VolulyteTM in Cardiac Surgery

Completed·FFresenius·Phase 4·NCT01553617·133 enrolled

Injury1 trial

Fluid Resuscitation in Patients Suffering From Burns Injury

Terminated·FFresenius·Phase 4·NCT01689506·11 enrolled

3 more indications

Mortality1 trial

Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis

Completed·NNanfang Hospital, Southern Medical University··NCT06874634·180 enrolled

Ascites1 trial

Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

Completed·PProtgen Ltd·Phase 2/3·NCT06553456·390 enrolled

Unspecified2 trials

Recombinant Human Serum Albumin in Healthy Subjects

Completed·PProtgen Ltd·Phase 1·NCT05179265·48 enrolled

Voluven® in Paediatric Patients

Completed·FFresenius·Phase 4·NCT00860405·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Human serum albumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human serum albumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human serum albumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fresenius company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFresenius

Human serum albumin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Head Injury1 trial

Phase II1 trial

Cirrhosis1 trial

Cardiac Surgery1 trial

Injury1 trial

Mortality1 trial

Ascites1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News